Department of Pediatric Oncology, University Hospital, Angers, France.
Kervision - Polyclinique de l'Atlantique, Nantes-Saint Herblain, France.
PLoS One. 2019 Mar 8;14(3):e0212107. doi: 10.1371/journal.pone.0212107. eCollection 2019.
Visual outcome is one of the main issues in the treatment of optic pathway glioma in childhood. Although the prognostic factors of low vision have been discussed extensively, no reliable indicators for visual loss exist. Therefore, we aimed to define initial and evolving factors associated with long-term vision loss.
We conducted a multicenter historical cohort study of children treated in France with up-front BB-SFOP chemotherapy between 1990 and 2004. Visual acuity performed at the long-term follow-up visit or within 6 months prior was analyzed. Logistic regression analysis was used to estimate the effects of clinical and radiological factors on long-term visual outcome.
Of the 180 patients in the cohort, long-term visual acuity data were available for 132 (73.3%) patients (median follow-up: 14.2 years; range: 6.1-25.6). At the last follow-up, 61/132 patients (46.2%) had impaired vision, and 35 of these patients (57.3%) were partially sighted or blind. Multivariate analysis showed that factors associated with a worse prognosis for long-term visual acuity were an age at diagnosis of < 1 year (OR 3.5 [95% CI: 1.1-11.2], p = 0.04), tumor extent (OR 4.7 [95% CI: 1.2-19.9], p = 0.03), intracranial hypertension requiring one or more surgical procedures (OR 5.6 [95% CI: 1.8-18.4], p = 0.003), and the need for additional treatment after initial BB-SFOP chemotherapy (OR 3.5 [95% CI: 1.1-11.9], p = 0.04). NF1 status did not appear as a prognostic factor, but in non-NF1 patients, a decrease in tumor volume with contrast enhancement after BB-SFOP chemotherapy was directly associated with a better visual prognosis (OR 0.8 [95% CI: 0.8-0.9], p = 0.04).
Our study confirms that a large proportion of children with optic pathway glioma have poor long-term outcomes of visual acuity. These data suggest new prognostic factors for visual acuity, but these results need to be confirmed further by large- and international-scale studies.
视觉预后是儿童视神经胶质瘤治疗中的主要问题之一。尽管已经广泛讨论了低视力的预后因素,但仍没有可靠的视力丧失指标。因此,我们旨在确定与长期视力丧失相关的初始和进展因素。
我们对 1990 年至 2004 年期间在法国接受一线 BB-SFOP 化疗治疗的儿童进行了一项多中心历史队列研究。分析了长期随访或 6 个月内进行的视力检查结果。使用逻辑回归分析来评估临床和影像学因素对长期视觉结局的影响。
在该队列的 180 名患者中,132 名(73.3%)患者可获得长期视力数据(中位随访时间:14.2 年;范围:6.1-25.6 年)。在最后一次随访时,61/132 名患者(46.2%)视力受损,其中 35 名患者(57.3%)为部分失明或失明。多变量分析显示,与长期视力预后较差相关的因素包括诊断时年龄<1 岁(OR 3.5 [95%CI:1.1-11.2],p=0.04)、肿瘤范围(OR 4.7 [95%CI:1.2-19.9],p=0.03)、需要进行一次或多次手术以治疗颅内压升高(OR 5.6 [95%CI:1.8-18.4],p=0.003),以及在初始 BB-SFOP 化疗后需要额外治疗(OR 3.5 [95%CI:1.1-11.9],p=0.04)。NF1 状态似乎不是一个预后因素,但在非 NF1 患者中,BB-SFOP 化疗后肿瘤体积缩小伴对比增强与更好的视力预后直接相关(OR 0.8 [95%CI:0.8-0.9],p=0.04)。
我们的研究证实,很大一部分视神经胶质瘤患儿的长期视力预后较差。这些数据提示了新的视力预后因素,但这些结果需要通过大样本和国际规模的研究进一步证实。